Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07388511 · ClinicalTrials.gov registry record · Phase 1
A Study of Elenestinib in Healthy Adult Female Participants
A Phase 1 study of Healthy Participants, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07388511 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 20 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07388511, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Levonorgestrel/Ethinyl Estradiol
- DRUG Elenestinib
Study Locations (1)
Arizona
- Celerion, Inc - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07388511
The ClinicalTrials.gov registry entry for NCT07388511 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (69% lower). The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Midazolam is the first listed.
NCT07388511 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT07388511 about?
NCT07388511 is a clinical study titled "A Study of Elenestinib in Healthy Adult Female Participants". The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estra...
What is the current status of trial NCT07388511?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-03. Estimated completion is 2026-04-01.
What conditions does trial NCT07388511 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07388511?
The interventions under investigation include: Midazolam (DRUG), Levonorgestrel/Ethinyl Estradiol (DRUG), Elenestinib (DRUG).
Who is sponsoring clinical trial NCT07388511?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07388511 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.